These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21094929)

  • 1. Where do we stand in enzyme replacement therapy in Pompe's disease?
    van der Ploeg AT
    Neuromuscul Disord; 2010 Dec; 20(12):773-4. PubMed ID: 21094929
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Pompe's disease with recombinant enzymes].
    Van Hove JL
    Verh K Acad Geneeskd Belg; 1998; 60(4):347-57. PubMed ID: 9883081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow transplantation for Pompé's disease.
    Hoogerbrugge PM; Wagemaker G; van Bekkum DW; Reuser AJ; vd Ploeg AT
    N Engl J Med; 1986 Jul; 315(1):65-6. PubMed ID: 3086726
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiomyopathy in Pompe's disease.
    Fayssoil A
    Eur J Intern Med; 2008 Jan; 19(1):57-9. PubMed ID: 18206603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Enzyme replacement therapy in Pompe's disease].
    Merk T; Wibmer T; Schumann C; Krüger S
    Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acid alpha-glucosidase deficiency: Pompe's disease].
    Iwamasa T
    Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):686-92. PubMed ID: 3152090
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycogen storage disease type II (Pompe's disease): the first biochemical evidence in Thailand.
    Rangdaeng S; Scollard DM; Srichairatanakol S; Sutthachit M; Phornphutkul C
    J Med Assoc Thai; 1987 Sep; 70(9):536-42. PubMed ID: 2960768
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
    Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
    Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
    Lin CY; Ho CH; Hsieh YH; Kikuchi T
    Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.
    van Capelle CI; van der Beek NA; Hagemans ML; Arts WF; Hop WC; Lee P; Jaeken J; Frohn-Mulder IM; Merkus PJ; Corzo D; Puga AC; Reuser AJ; van der Ploeg AT
    Neuromuscul Disord; 2010 Dec; 20(12):775-82. PubMed ID: 20817528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition.
    Remiche G; Herbaut AG; Ronchi D; Lamperti C; Magri F; Moggio M; Bresolin N; Comi GP
    Eur Neurol; 2012; 68(2):75-8. PubMed ID: 22760201
    [No Abstract]   [Full Text] [Related]  

  • 15. More on bone marrow transplantation for glycogen storage disease type II (Pompé's disease).
    Hug G
    N Engl J Med; 1986 Nov; 315(19):1229. PubMed ID: 3531866
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzyme Replacement Therapy Provides Effective, Long-Term Treatment of Cardiomyopathy in Pompe Disease.
    Baba S; Yoshinaga D; Akagi K; Matsuda K; Yokoyama A; Yoshida T; Hirata T
    Circ J; 2018 Nov; 82(12):3100-3101. PubMed ID: 29848885
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzyme replacement therapy in an infant with Pompe's disease with severe cardiomyopathy.
    Tanzer F; Buyukkayhan D; Cansu Mutlu E; Kalender Korkmaz F
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1159-62. PubMed ID: 20333876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy for infantile-onset pompe disease: curse or cure?
    Willems J; Petros A; Brierley J
    Neurology; 2008 Jul; 71(5):380-1. PubMed ID: 18663187
    [No Abstract]   [Full Text] [Related]  

  • 19. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen storage disease type II in Israel.
    Bashan N; Potashnik R; Barash V; Gutman A; Moses SW
    Isr J Med Sci; 1988; 24(4-5):224-7. PubMed ID: 3132435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.